Aduhelm
Biogen Pulls the Plug on Alzheimer’s Drug Aducanumab
Biogen announced on Jan. 31 that it would abandon the development and commercialization of aducanumab (Aduhelm), ...
FEBRUARY 2, 2024
Aducanumab Coverage With Evidence Development Decision a ‘Unique’ NCD, CMS Leaders Say
The decision by the Centers for Medicare & Medicaid Services (CMS) to cover the controversial Alzheimer’s ...
MAY 11, 2022
CMS Issues Final Aducanumab Coverage Decision
CMS finalized its Medicare coverage policy for the controversial Alzheimer’s disease drug Aduhelm.
APRIL 11, 2022
Medicare to Restrict Aducanumab Coverage
CMS has announced a preliminary National Coverage Determination restricting Medicare coverage of the ...
JANUARY 12, 2022
Some Stakeholders Put the Breaks on Alzheimer's Drug
Several months after the FDA’s controversial decision to approve Aduhelm, payors are still determining how ...
SEPTEMBER 8, 2021
FDA Narrows Aduhelm Label
The FDA recently updated the label for Biogen's controversial Alzheimer’s drug.
JULY 12, 2021